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months. Methods: In PRIME, 1183 patients with previously untreated mCRC 
were randomised. Using data from an exploratory analysis conducted when 80% 
of patients had died, NNTs (Bender. Encyclopedia of Biostatistics, Second Edition; 
Volume 6, pp3752-61) were retrospectively calculated in patients with KRAS/NRAS 
WT (n= 505; exons 2-4 assessed) mCRC overall and in the ECOG performance score 
0/1 (n= 473) subgroup. ORR and PFS events were defined using RECIST. Results: 
In the overall KRAS/NRAS WT population, 59.3% vs 45.6% of patients receiving 
panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, achieved an OR; NNT(95% 
CI) in the ORR analysis was 7.3(4.5-19.9). In the ECOG 0/1 subgroup, 61.3% vs 46.4% 
of those receiving panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, had an 
OR; the NNT(95% CI) was 6.7(4.2-16.5). For the PFS overall population analysis, the 
HR(95% CI) was 0.74(0.62-0.90); HR(95% CI) for the ECOG 0/1 subgroup was 0.72(0.59-
0.88). NNTs(95% CI) in the overall population at 6 and 12 months were 12.8(8.3-34.1) 
and 9.2(5.7-25.9), respectively; corresponding values for the ECOG 0/1 subgroup were 
11.9(7.9-27.8) and 8.4(5.3-20.8). For the OS overall population analysis, the HR(95% 
CI) was 0.76(0.63-0.93); HR(95% CI) for the ECOG 0/1 subgroup was 0.74(0.60-0.90). 
NNTs(95% CI) in the overall population at 12 and 24 months were 16.8(10.4-57.1) and 
10.4(6.2-37.1), respectively; corresponding values for the ECOG 0/1 subgroup were 
16.0(10.3-44.1) and 9.4(5.9-27.2). ConClusions: In these analyses NNTs for PFS, 
OS and particularly ORR were low, reflecting the high therapeutic benefit of adding 
panitumumab to FOLFOX4 in patients with KRAS/NRAS WT mCRC. Limitation by 
ECOG score 0/1 further lowered NNTs for PFS and OS.
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objeCtives: T-DM1, an antibody-drug conjugate which combines the antitumor 
properties of trastuzumab (H) with the cytotoxic agent DM1, is approved for the 
treatment of patients with MBC previously treated with trastuzumab+taxane. We 
compared the clinical effectiveness of T-DM1 versus all available therapies used in 
the treatment of unresectable HER2-positive locally advanced breast cancer (LABC) 
or MBC. Methods: This systematic review (SR) and indirect treatment comparison 
(ITC) included all published data between January 1, 1998 and December 20, 2012. 
Studies were chosen in accordance with conventional methods for performing and 
reporting SRs and ITCs (i.e., Cochrane Handbook for SRs, PRISMA, ISPOR guidelines, 
and major HTA agencies). Eligible trials were controlled trials of treatments for 
unresectable HER2-positive LABC or MBC that had progressed after treatment with 
combination of trastuzumab+taxane in the adjuvant or MBC setting. Progression 
had to have occurred after the most recent treatment for LABC or MBC or within 6 
months after treatment for early-stage disease. Results: Seven RCTs and two non-
randomized controlled trials (n-RCTs) met the inclusion criteria. Of the seven RCTs, 
five had a common comparator, being eligible for the ITC. The other two RCTs and 
two n-RCTs did not have a common comparator and were thus not included in the 
ITC. T-DM1 was the only treatment to demonstrate statistically significantly longer 
overall survival (OS) and progression-free survival (PFS) when directly compared to 
capecitabine+lapatinib, and when indirectly compared to capecitabine+trastuzumab 
(PFS HR [95% CI]: 0.53 [0.32, 0.86], p= 0.01; OS HR [95% CI]: 0.56 [0.35, 0.91]; p= 0.01) 
and capecitabine monotherapy (PFS HR [95% CI]: 0.36 [0.25, 0.51]; p< 0.0001); OS (HR 
[95% CI]: 0.53 (0.39, 0.72); p= 0.0009). ConClusions: In this ITC, T-DM1 was associ-
ated with longer OS and PFS versus capecitabine+trastuzumab and capecitabine 
monotherapy in patients with HER2-positive LABC or MBC with disease progression 
after treatment with trastuzumab+taxane.
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objeCtives: To investigate the efficacy and safety of second-line chemotherapy in 
mCRC and to determine the feasibility of relative efficacy between treatments using 
indirect or mixed treatment comparisons. Methods: An SLR on randomized trials 
published from 1992–2012 was performed. EMBASE, PubMed, CENTRAL databases 
were consulted. Manual searches (including ASCO and ESMO abstracts) were also 
conducted. Eligible studies evaluated second-line clinical efficacy and safety end-
points in mCRC. Results: Twenty-seven trials with patients enrolled ranging from 
n= 33–1,226 were identified. Patients were markedly diverse in terms of ECOG, EGFR, 
or KRAS status, and prior treatment exposures: oxaliplatin (k= 9), irinotecan +/- 5-FU 
(k= 5), bevacizumab (k= 7), and 5-FU (k= 22). On-study treatments and comparators 
were also diverse: FOLFIRI alone (t= 6) or with panitumumab (t= 2) or aflibercept 
(t= 1); FOLFOX4 alone (t= 6) or with bevacizumab (t= 1); bevacizumab alone (t= 1) or 
with chemotherapy (t= 2); irinotecan alone (t= 19) or with FOLFOX4 (t= 2) or cetuxi-
mab (t= 1); and miscellaneous other regimens (t= 19). Study methodologies varied 
in analysis populations (ITT [k= 24] vs. per protocol or not reported [k= 3]), primary 
efficacy outcomes (OS, PFS, and/or tumor response, as variably measured), follow-up 
durations, and timing of outcomes measurements. Preliminary network diagrams to 
assess feasibility of meta-analyses for ITC revealed only a single study for each treat-
ment comparison of interest. Assumptions of comparability of apparently diverse 
patients, past and current treatment regimens, and comparator arms would be 
necessary to pool treatment groups for meta-analysis of treatment effectiveness 
across studies and hence, is not feasible. Given the lack of SOC treatments used in 
many trials, introducing such assumptions will compromise the evidence-based 
criteria for quantitative clinical data syntheses for indirect or mixed treatment 
Fixed and random effects models were explored with results reported for the best 
fitting model. Hazard ratio (HR) was chosen as the summary statistic. Results: The 
network of 6 RCTs formed a linear series of “steps”, which facilitated comparison of 
all chemotherapy regimens of interest. The fixed effects model was the best-fitting 
model. There was reasonable agreement between the number of unconstrained 
data points, residual deviance and pair-wise results, suggesting a coherent network. 
Using bevacizumab/gemcitabine/carboplatin as the baseline, the results for PFS 
for the other chemotherapy regimens were: platinum monotherapy (HR 2.92, 95% 
Credible Interval [CrI]: 2.10 to 3.96), gemcitabine/carboplatin (HR 2.09, 95% CrI: 1.65 
to 2.60), paclitaxel/carboplatin (HR 2.16, 95% CrI: 1.50 to 3.01), PLDH/carboplatin (HR 
1.77, 95% CrI: 1.20 to 2.51); where a HR> 1 favours bevacizumab/gemcitabine/carbo-
platin and a HR< 1 favours the comparator. ConClusions: This research suggests 
bevacizumab in combination with gemcitabine/carboplatin may offer significantly 
longer PFS compared with other chemotherapy options available in the UK.
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objeCtives: Brentuximab vedotin (ADCETRIS®), a CD30-targeted antibody-drug 
conjugate, has conditional approval in Europe for the treatment of adult patients 
with RR sALCL. This systematic review summarized the efficacy of other treatments 
for RR ALCL, for comparison with brentuximab vedotin. Methods: A systematic 
literature review identified studies published between 1993 and February 2013 report-
ing efficacy of treatments in adult patients with RR ALCL, or more generally with RR 
peripheral T-cell lymphoma (PTCL) including ≥ 1 ALCL patient. Five databases were 
included: EMBASE, MEDLINE, and the WHO ICTRP; reviews published since 2011 were 
also searched manually for additional studies. English publications reporting com-
plete remission/response (CR) rate and/or 2-year overall survival (OS) in RR ALCL/
PTCL populations were included. Publications of principal treatment with bone mar-
row transplantation or radiotherapy were excluded. CR rates and 2-year OS, from 
the identified studies and from the brentuximab vedotin single-arm phase 2 trial 
in sALCL (SG035-0004), were summarized. Results: Of 1653 publications screened, 
12 studies were eligible for inclusion; all were phase 1 or 2 or unspecified prospec-
tive non-randomized studies. For these studies, the CR rates were 0–28% in RR PTCL 
patients (n= 4–130 PTCL; median age 36–69 years; n= 1–41 ALCL), and for the 6 studies 
that also reported CR outcomes in the subset of RR ALCL patients (n= 13–130 PTCL; 
median age 47–69 years; n= 2–41 ALCL), the CR rates were 0–33% in RR ALCL patients. 
For RR ALCL patients treated with brentuximab vedotin in SG035-0004 (n= 58 sALCL; 
median age 52 years) the CR rate was 59%. The 2-year OS ranged from 7–33% in the 
5 identified studies that reported OS, compared with 63% with brentuximab vedotin 
in SG035-0004. ConClusions: The CR rate and 2-year OS for brentuximab vedotin 
in RR sALCL appear to exceed that of other therapies in RR ALCL/PTCL.
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objeCtives: Although gastric cancer has decreased in the last three decades, it is 
still the second leading cause of cancer death worldwide. In Asian countries, the 
burden of gastric cancer has remained, and screening is still expected to prevent 
gastric cancer death. In order to evaluate reduction of mortality from gastric cancer 
by endoscopic screening, a community-based, case-control study was conducted in 
Japan. Methods: Case subjects were defined as persons who had died of gastric 
cancer between 2003 and 2006 in four cities, Tottori Prefecture, and between 2006 
and 2010 in Niigata City, Japan. Up to six control subjects were matched by sex, birth 
year (±3 years), and residence of each corresponding case from population lists in the 
study areas. Controls were required to be disease-free at the time when the case was 
diagnosed gastric cancer. The odds ratios were calculated for those who had ever par-
ticipated in endoscopic screening or radiographic screening before the reference date 
when the case was diagnosed gastric cancer, compared with persons who had never 
participated in any screening. Conditional logistic-regression models for matched sets 
were used to estimate the odds ratios and 95% confidence intervals. Results: There 
were 288 males and 122 females for case subjects, with 2,292 matched control subjects. 
Compared with those who had never been screened before the date of diagnosis of 
gastric cancer in cases, the odds ratios within 48 months from the diagnosis date 
were 0.703 (95% confidence interval :0.497-0.996) for endoscopic screening and 0.860 
(95% confidence interval :0.631-1.171) for radiographic screening. ConClusions: The 
result suggests a 30% reduction from gastric cancer mortality by endoscopic screening 
compared to no screening within 48 months before the diagnosis date of gastric cancer.
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objeCtives: To calculate NNTs for panitumumab+FOLFOX4 vs FOLFOX4 alone 
(PRIME study) to achieve one objective response (OR rate [ORR] analysis) or pre-
vent one disease progression (PFS analysis) or death (OS analysis) at 6/12 or 12/24 
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benign and malignant cases. Results: In 2008-2009 there were 477904 screening 
mammography examinations in Hungary. 5.15 % of participating women were re-
called. The attendance of re-called women was 92.25 %. Altogether 2092 women 
(9.7 %) were referred for breast surgery but only 1485 women (71.0 %) underwent 
surgery. Histological examination confirmed 281 benign (18.9 %) and 1204 malignant 
(81.1 %) cases. ConClusions: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international pro-
fessional guidelines. However, in addition to current indicators, new ones should be 
introduced in order to provide a more comprehensive monitoring of the program.
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objeCtives: Organized, nationwide screening for breast cancer with mammog-
raphy started in Hungary in January 2002. Women in the age group 45-65 years 
are the target population and 2 years screening interval is applied. The aim of 
this study is to analyze the attendance rate of the 4th screening round (2008-
2009). Methods: The data derive from the financial database of the National 
Health Insurance Fund Administration (NHIFA) covering the period of 2008-2009. 
We calculated two attendance indicators. The up-take of the program means 
the percentage of women aged 45-65 who, having been sent an invitation for 
screening, attend a screening unit and undergo mammography in response to 
that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic mam-
mography. Results: In 2008-2009 there were 477904 screening mammography 
cases and 1204893 diagnostic mammography examinations in Hungary. We found 
49.4 % and 41.5 % up-take in 2008 and 2009 respectively; and 45.0 % combined 
rate for 2008/2009. The screening coverage was 31.2 % and the diagnostic cover-
age was 20.4 %, while the total coverage (screening and diagnostic) was 50.1 
%. ConClusions: The attendance of the Hungarian organized breast cancer 
screening program – compared to the previous period before the implementa-
tion of the organized screening program – is promising, although to achieve the 
expected results in mortality decrease a further improvement of both the uptake 
and coverage is necessary.
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objeCtives: Recent advances in prostate cancer radiation therapy (RT) technology 
have led to the development of costlier treatments such as intensity-modulated 
radiation therapy (IMRT) compared to the prior standard, conventional radiation 
therapy (CRT). This study examines the two treatment modalities to determine if 
racial disparities in morbidity and disease control may be explained by differential 
use of IMRT versus CRT. Methods: A population-based study was conducted 
using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 
from 2000 through 2009 for patients with non-metastatic prostate cancer. Adjusted 
Cox Proportional Hazards models were conducted, adjusting for demographic 
and clinical characteristics. Results are presented as (Adjusted Hazard Ratio [95% 
Confidence Interval]). In subjects without prior morbidity at RT, the rate of recur-
rence, hip fracture, erectile dysfunction, disorders related to gastrointestinal, 
and urinary (incontinence and non-incontinence) morbidity were compared by 
race with IMRT as the referent group. Results: Approximately 10,976 men [524 
African-American (AA) CRT; 423 AA IMRT; 4,746 Caucasian CRT; 5,283 Caucasian 
IMRT] met study eligibility. Diffusion of IMRT was slower among AA compared 
to Caucasians (p< 0.001). Caucasians receiving CRT were at a greater risk for hip 
fracture [1.29; (1.16, 1.43)], cancer recurrence [1.13; (1.04, 1.23)], or urinary incon-
tinence [1.09; (1.01, 1.19)] than those receiving IMRT. No estimates comparing 
AA CRT recipients to AA IMRT recipients reached statistical significance, though 
cancer recurrence, erectile dysfunction, and gastrointestinal morbidity rates were 
greater for CRT subjects ConClusions: There were no statistically significant 
racial disparities in morbidity and disease control related to differential use of 
IMRT versus CRT. However, diffusion of IMRT was significantly slower among AA. 
Future research should include more years of follow-up data and a larger sample 
of AA in order to understand whether measured differences in treatment diffusion 
achieve clinical significance sufficient to explain a portion of the racial disparity 
in prostate cancer mortality.
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comparisons. ConClusions: Current standards around second-line treatment of 
mCRC have evolved over time. The substantial clinical, methodological, and sta-
tistical heterogeneity in the available data prevents evidence-based quantitative 
comparisons of treatment outcomes at this time.
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objeCtives: This study compares everolimus (EVE) versus the most commonly 
used chemotherapy agents in UK clinical practice (capecitabine [CAPE], docetaxel 
[DOC] and doxorubicin [DOX]) in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer with the purpose of determining 
the effect of everolimus versus chemotherapy through the derivation of hazard 
ratios (HR). Methods: A systematic review of the literature was performed to find 
evidence that could link EVE with chemotherapy (CAPE, DOC and DOX) in terms 
of progression-free survival (PFS) and overall survival (OS). No head-to-head tri-
als comparing EVE versus chemotherapy were found, the only study that linked 
hormonal therapy with chemotherapy for treatment of metastatic breast cancer 
was Wilcken et al. (2003). Wilcken et al. identified three studies which compared 
OS for tamoxifen versus chemotherapy. None of the studies identified in the sys-
tematic review reported PFS. The link between EVE versus chemotherapy through 
Wilcken et al.(2003) was established via tamoxifen (using Bucher methods), so it 
was assumed that PFS for chemotherapy would be the same as PFS for everolimus 
versus tamoxifen (TAM) from the TAMRAD trial. Results: HR for everolimus versus 
tamoxifen for PFS from the TAMRAD trial is 0.54. For OS, Wilcken et al. derived a HR 
for chemotherapy versus tamoxifen of 0.94. To calculate the HR for OS for everoli-
mus vs tamoxifen the inverse was applied to the OS HR from the TAMRAD trial 
(0.45), hence (1/0.45)= 2.22. The HR for OS for everolimus versus chemotherapy is 
therefore (0.94x2.22)= 2.09. Because a class effect was assumed for the three chemo-
therapy agents, these HRs were applied to capecitabine, docetaxel and doxorubicin 
equally. ConClusions: Compared with the most commonly used chemotherapy 
agents in UK clinical practice (CAPE, DOC and DOX), everolimus has a lower risk of 
death as demonstrated by the HRs derived.
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objeCtives: Lung cancer is the most common cause of cancer-related deaths 
world-wide. Afatinib is a novel, potent, irreversible ErbB family blocker. In EGFR 
mutation-positive locally advanced and metastatic non-small cell lung cancer, 
afatinib shows superior effectiveness as a 1st-line treatment compared to stand-
ard-of-care chemotherapy. To date, no head-to-head trial results exist to compare 
the efficacy of afatinib to reversible EGFR TKIs, gefitinib or erlotinib. The analy-
ses presented here attempt to fill this gap by means of a network meta-analysis 
(NMA). Methods: A systematic literature review (2002-2012) identified the best 
available evidence. Results from afatinib’s pivotal trials (LUX-Lung 3, LUX-Lung 6) 
were added. A NMA following a Bayesian approach (in WinBUGS) was applied to 
estimate the relative treatment effects between afatinib, gefitinib and erlotinib. 
Outcomes of interest were progression free survival (PFS) and overall survival (OS). 
For PFS, results by investigator review were considered as not in all trials PFS was 
assessed independently. Versus erlotinib, afatinib’s results in the two most common 
EGFR mutations studied in erlotinib trials were considered. Sensitivity analyses were 
performed to confirm the robustness of results. Results: Twenty studies, includ-
ing LUX-Lung 3 and LUX-Lung 6, were included; 19 reported OS, 14 reported PFS. 
Results from random effects models are reported. All comparisons versus reversible 
TKIs favoured afatinib, although in most analyses the upper credible interval limit 
exceeded 1. The estimated probability of afatinib being best regarding PFS in all 
mutations was 80% compared to 17% for erlotinib and 3% for gefitinib, and was 43% 
regarding OS compared to 13% for gefitinib and 3% for erlotinib. ConClusions: 
Afatinib consistently showed superior efficacy versus chemotherapy in the pivotal 
trials. In the absence of head-to-head trial results versus reversible TKIs, the NMA 
results suggest also potential superiority of afatinib for both PFS and OS when 
compared to erlotinib and gefitinib.
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objeCtives: Organized, nationwide screening for breast cancer with mammogra-
phy started in Hungary in January 2002. Women in the age group 45-65 years are the 
target population and 2 years screening interval is applied. The aim of this study is 
to evaluate the quality indicators of the 4th screening round (2008-2009). Methods: 
The data derive from the financial database of the National Health Insurance Fund 
Administration (NHIFA) covering the period of 2008-2009. We calculated the follow-
ing indicators: recall rate of women who underwent mammography examinations, 
attendance of re-called women, proportion of women referred to surgery, proportion 
of women who underwent surgery compared to referred women, proportion of 
